TROPHAMINE 10%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROPHAMINE 10% (TROPHAMINE 10%).
Trophamine 10% is an amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients unable to tolerate oral or enteral nutrition. It acts as a substrate for protein synthesis, thereby promoting tissue repair and maintenance.
| Metabolism | Amino acids are metabolized via hepatic transamination, deamination, and urea cycle pathways. Individual amino acids undergo specific catabolic pathways (e.g., branched-chain amino acids metabolized in muscle, aromatic amino acids in liver). |
| Excretion | Renal: 98% as amino acids and peptides; fecal: <2% |
| Half-life | Not applicable; amino acids rapidly cleared from plasma with half-life of 10-30 minutes due to tissue uptake and metabolism |
| Protein binding | Negligible (<5%) for free amino acids; not significantly bound to plasma proteins |
| Volume of Distribution | 0.15-0.25 L/kg (primarily confined to extracellular fluid) |
| Bioavailability | Intravenous: 100% |
| Onset of Action | Intravenous: within minutes (rise in plasma amino acid concentrations) |
| Duration of Action | Intravenous: 2-4 hours (until amino acids are distributed and metabolized) |
| Molecular Weight | Average molecular weight of amino acids: approximately 110 Da (range 75-204 Da). |
Intravenous infusion, 500 mL to 2 L per day, typically administered at a rate of 125-200 mL/hour. Dosage individualized based on protein and caloric requirements.
| Dosage form | INJECTABLE |
| Renal impairment | In patients with renal impairment, reduce total protein intake; contraindicated in severe renal failure (eGFR < 30 mL/min/1.73 m²) unless dialysis is being performed. Monitor BUN and serum electrolytes. |
| Liver impairment | Contraindicated in patients with hepatic coma or severe hepatic impairment (Child-Pugh class C). Use with caution in Child-Pugh class B, monitor ammonia levels. |
| Pediatric use | Infants and children: 0.5-3.0 g/kg/day of amino acids, administered intravenously. Rate and volume adjusted based on age, weight, and clinical condition. |
| Geriatric use | No specific dose adjustment; however, consider age-related decline in renal function and monitor fluid and electrolyte balance closely. Start at lower end of dosing range. |
| 1st trimester | No adequate studies; use only if clearly needed. Essential amino acids are required for fetal development; however, safety in first trimester has not been established. |
| 2nd trimester | May be used if maternal benefit outweighs potential fetal risk. No known teratogenic effects from balanced amino acid solutions. |
| 3rd trimester | May be used if indicated; monitor for electrolyte imbalances. No specific fetal risks reported. |
Clinical note
Comprehensive clinical and safety monograph for TROPHAMINE 10% (TROPHAMINE 10%).
| Placental transfer | Amino acids are actively transferred across placenta; levels in fetal circulation correspond to maternal levels. Clinical significance depends on maternal metabolic status. |
| Breastfeeding | Amino acids are normal components of breast milk; administration of balanced amino acid solutions is compatible with breastfeeding. Caution in mothers with metabolic disorders. |
■ FDA Black Box Warning
There is no FDA black box warning for Trophamine 10%.
| Serious Effects |
Hypersensitivity to any componentInborn errors of amino acid metabolismSevere electrolyte imbalancesPulmonary edemaSevere hepatic insufficiencySevere renal impairment with oliguria
| Precautions | Risk of hyperglycemia in diabetic or stressed patients; monitor blood glucose., Electrolyte imbalances, particularly hyperkalemia or hypophosphatemia, may occur upon refeeding; monitor electrolytes., Fluid overload in patients with renal or cardiac impairment., Metabolic acidosis with prolonged use., Infectious complications from central venous catheter use. |
| Food/Dietary | No specific food interactions. However, concurrent dietary protein intake should be monitored to avoid excess nitrogen load. Ensure adequate caloric intake from carbohydrates and fats to spare amino acids for protein synthesis. |
Loading safety data…
| Lactation Rating | L2 |
| Teratogenic Risk | TROPHAMINE 10% is an amino acid solution. Limited data in pregnancy; no malformations reported in animal studies. Inadequate human data. Potential risks from electrolyte imbalances or metabolic disturbances. First trimester: no known teratogenicity. Second/third trimester: use only if clearly needed; monitor for fluid/electrolyte imbalances. |
| Fetal Monitoring | Monitor serum electrolytes, blood glucose, renal function, and acid-base status. Assess for signs of fluid overload or metabolic alkalosis. Fetal monitoring as clinically indicated. |
| Fertility Effects | No known adverse effects on fertility. |
| Clinical Pearls | TROPHAMINE 10% is a peripheral parenteral amino acid solution used to prevent nitrogen loss and promote protein synthesis. Administer via central line to avoid phlebitis. Monitor serum electrolytes, BUN, and glucose. Use with caution in patients with renal or hepatic impairment. Ensure adequate non-protein calories (dextrose/lipids) to prevent amino acid utilization for gluconeogenesis. |
| Patient Advice | This medication is given through a vein to provide protein for your body. · Report any signs of infection (redness, swelling, pain) at the infusion site. · You may need regular blood tests to monitor your kidney and liver function. · Do not stop the infusion without consulting your healthcare provider. · Inform your doctor if you have diabetes, kidney disease, or liver disease. |